Latest Breaking News On - Trishula therapeutics - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United statesEteläuomen läiSouth koreaJin wangGenentechf hoffmannAsher biotherapeuticsDaiichi sankyoChipscreen biosciencesBristol myers squibbAshfield medcommsMerck biopharmMerck seronoSamsung bioepisLyell immunopharmaCalithera biosciencesEli lilly

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesGettysburg collegeJohn hohnekerShveta digheBurroughs wellcomeSanford zweifachChidozie ugwumbaTrishula therapeutics incGlobal head of developmentRutgers school of biomedicalBiotheryx incDimension therapeutics incBoard of directors curis incSonata therapeutics incTorque therapeutics inc

Carisma Therapeutics (CARM) Announces Board Changes

Carisma Therapeutics (CARM) Announces Board Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesBurroughs wellcomeSanford zweifachJohn hohnekerChidozie ugwumbaUniversity of medicineEvelo biosciences incRutgers medical schoolAravive incAudit committee of the boardUniversity of north carolina at chapel hillTrishula therapeutics incGlobal head of developmentBiotheryx incDimension therapeutics inc

Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients

/PRNewswire/ Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today announced the initiation of a randomized Phase 2.

Julie rathbunPrnewswire trishula therapeutics incAbbvie incRathbun communicationsAnil singhalChief executive officerTrishula therapeutics

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis-free vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Astellas pharmaImmatics incyteCrown bioscienceJason lukeImmunocore incytePembrolizumab keytrudaTrex bioCodiak biosciencesBristol myers squibbHillman cancer centerCancer immunotherapeutic centerGilead sciencesImmunotherapy programCstone pharmaceuticalsTizona therapeutics incDivision of hematology oncology